Literature DB >> 29933824

New and Emerging Illicit Psychoactive Substances.

Ryan Graddy1, Megan E Buresh1, Darius A Rastegar2.   

Abstract

Several novel psychoactive substances have emerged in recent years. Users are typically young men who use other substances. In the category of stimulants, cathinones ("bath salts") have predominated and can lead to agitation, psychosis, hyperthermia, and death. Synthetic cannabinoids ("spice") are more potent than marijuana and can lead to agitation, psychosis, seizures, and death. There are no rapid tests to identify these substances and general treatment includes benzodiazepines for agitation and supportive therapy. Many Synthetic opioids are potent analogues of fentanyl and carry a high risk of overdose. In addition, there are several designer benzodiazepines that have emerged.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cannabinoids; Cathinones; Designer drugs; Novel psychoactive substances; Psychotropic drugs

Mesh:

Substances:

Year:  2018        PMID: 29933824     DOI: 10.1016/j.mcna.2018.02.010

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  10 in total

1.  Emerging threats in addiction: will novel psychoactive substances contribute to exacerbating the ongoing drug overdose epidemic?

Authors:  F Scott Hall; Klaus A Miczek
Journal:  Psychopharmacology (Berl)       Date:  2019-03       Impact factor: 4.530

Review 2.  The Bridge Between Classical and "Synthetic"/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective.

Authors:  Laura Orsolini; Stefania Chiappini; Duccio Papanti; Domenico De Berardis; John M Corkery; Fabrizio Schifano
Journal:  Front Psychiatry       Date:  2019-11-20       Impact factor: 4.157

3.  Pharmacotherapy of Patients Taking New Psychoactive Substances: A Systematic Review and Analysis of Case Reports.

Authors:  Michal Ordak; Aleksandra Zmysłowska; Miłosz Bielski; Daniel Rybak; Maja Tomaszewska; Katarzyna Wyszomierska; Aleksandra Kmiec; Natalia Garlicka; Maria Zalewska; Michal Zalewski; Tadeusz Nasierowski; Elzbieta Muszynska; Magdalena Bujalska-Zadrozny
Journal:  Front Psychiatry       Date:  2021-04-23       Impact factor: 4.157

4.  New Psychoactive Substances Consumption in Opioid-Use Disorder Patients.

Authors:  Maria Alías-Ferri; Manuela Pellegrini; Emilia Marchei; Roberta Pacifici; Maria Concetta Rotolo; Simona Pichini; Clara Pérez-Mañá; Esther Papaseit; Robert Muga; Francina Fonseca; Marta Torrens; Magí Farré
Journal:  Biology (Basel)       Date:  2022-04-22

5.  Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds.

Authors:  Elise Wouters; Jolien Walraed; Michael Joseph Robertson; Max Meyrath; Martyna Szpakowska; Andy Chevigné; Georgios Skiniotis; Christophe Stove
Journal:  ACS Pharmacol Transl Sci       Date:  2019-11-04

6.  Rapid Identification of Novel Psychoactive and Other Controlled Substances Using Low-Field 1H NMR Spectroscopy.

Authors:  Lysbeth H Antonides; Rachel M Brignall; Andrew Costello; Jamie Ellison; Samuel E Firth; Nicolas Gilbert; Bethany J Groom; Samuel J Hudson; Matthew C Hulme; Jack Marron; Zoe A Pullen; Thomas B R Robertson; Christopher J Schofield; David C Williamson; E Kate Kemsley; Oliver B Sutcliffe; Ryan E Mewis
Journal:  ACS Omega       Date:  2019-04-19

7.  Editorial: New Trends of Substance Abuse: Looking for New Psychotropic Effects of Chem Sex Drugs, Cognitive Enhancers, and New Psychoactive Substances.

Authors:  Simona Pichini; Annagiulia Di Trana; Marta Torrens; Norbert Scherbaum; Simona Zaami
Journal:  Front Psychiatry       Date:  2020-11-23       Impact factor: 4.157

8.  Synthetic cannabinoids use in a sample of opioid-use disorder patients.

Authors:  María Alías-Ferri; Manuela Pellegrini; Emilia Marchei; Roberta Pacifici; Maria Concetta Rotolo; Simona Pichini; Clara Pérez-Mañá; Esther Papaseit; Robert Muga; Francina Fonseca; Magi Farré; Marta Torrens
Journal:  Front Psychiatry       Date:  2022-08-03       Impact factor: 5.435

Review 9.  Designer Benzodiazepines: A Review of Toxicology and Public Health Risks.

Authors:  Pietro Brunetti; Raffaele Giorgetti; Adriano Tagliabracci; Marilyn A Huestis; Francesco Paolo Busardò
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11

10.  A Difficult Challenge for the Clinical Laboratory: Accessing and Interpreting Manufacturer Cross-Reactivity Data for Immunoassays Used in Urine Drug Testing.

Authors:  Justine M Reschly-Krasowski; Matthew D Krasowski
Journal:  Acad Pathol       Date:  2018-11-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.